Skip to main content
Fig. 3 | Clinical Hypertension

Fig. 3

From: Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

Fig. 3

Least squares mean change from baseline to week 6 in trough sitting clinic systolic blood pressure and sitting clinic diastolic blood pressure. aThe LS mean difference in change from baseline (95% CI) in AZL-M 40 mg versus placebo (mm Hg [95% CI]). bThe LS mean difference in change from baseline (95% CI) in AZL-M 80 mg versus placebo (mm Hg [95% CI]). ***p < 0.001 compared with placebo. Overall treatment effect is statistically significant at 0.05 at all visits for both trough scSBP and scDBP. AZL-M, azilsartan medoxomil; CI, confidence interval; LS, least squares; scDBP, sitting clinic diastolic blood pressure; scSBP, sitting clinic systolic blood pressure

Back to article page